Results 111 to 120 of about 71,730 (287)

3D spine shape estimation from single 2D DXA [PDF]

open access: yes
Scoliosis is currently assessed solely on 2D lateral deviations, but recent studies have also revealed the importance of other imaging planes in understanding the deformation of the spine.
Zisserman, Andrew   +2 more
core   +1 more source

Baseline characteristics of TDF2 DXA sub study participants who had at least one DXA bone mineral density scan at forearm, spine and hip: Botswana, 2007–2010. [PDF]

open access: yes, 2014
aThese are the 74 participants that only had a baseline DXA scan.bThese are the 147 participants that had at least one follow-up DXA scan (Longitudinal cohort).
Charles Rose (534787)   +8 more
core   +1 more source

Renal function in African women receiving tenofovir disoproxil fumarate as pre‐exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial

open access: yesHIV Medicine, EarlyView.
Abstract Background The effect of tenofovir disoproxil fumarate (TDF) when used as pre‐exposure prophylaxis (PrEP) on renal function in pregnant and postpartum women is understudied. An open‐label clinical trial (CAP016 study) was designed to examine the safety of TDF‐PrEP use during pregnancy and breastfeeding.
Gaysheen Kistan   +5 more
wiley   +1 more source

DXA: New concepts and tools beyond bone mineral density [PDF]

open access: yes
Since its introduction in 1987, dual-energy X-ray absorptiometry (DXA) has revolutionized bone assessment, becoming the gold standard for measuring bone mineral density (BMD).
Bongiorno, Alessia   +5 more
core   +1 more source

UltRaSoUnd‐guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study

open access: yesHIV Medicine, EarlyView.
Abstract Objectives We aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction‐associated steatotic liver disease (MASLD) in a cohort of middle‐aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis.
Mariacristina Poliseno   +13 more
wiley   +1 more source

Áhrif offitu á gæði beinþéttnimælinga. Samanburður á DXA og QCT [PDF]

open access: yes, 2014
Inngangur: Offita verður sífellt stærra vandamál í heiminum og mikilvægt er að skoða mæliaðferðir á hinum ýmsu þáttum svo hægt sé að rannsaka alla á nákvæman hátt, óháð stærð og þyngd.
Hildur Kjartansdóttir 1989-
core  

Areal BMD and the structural derivates by DXA. [PDF]

open access: yes, 2014
Areal BMD and the structural derivates by DXA.
Helene Buffat (523098)   +7 more
core   +1 more source

Appropriateness of bone density measurement in Switzerland: a cross-sectional study

open access: yesBMC Public Health, 2018
Background According to the WHO, osteoporosis is one of the most important non- communicable diseases worldwide. Different screening procedures are controversially discussed, especially concerning the concomitant issues of overdiagnosis and harm caused ...
Stefan Zechmann   +6 more
doaj   +1 more source

Bone health in adults with non‐ambulatory neuromuscular disorders: scoping review of risk factors, diagnosis and management

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Non‐ambulatory adults have an increased risk of osteoporosis and fractures due to reduced weight‐bearing and diminished neuromuscular stimulation, resulting in substantial morbidity and mortality. Aims This scoping review aimed to systematically evaluate risk factors, diagnostic indicators and management strategies for optimising ...
Thomas Bailey   +4 more
wiley   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

open access: yesInternal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Home - About - Disclaimer - Privacy